Procurement Summary
Country : USA
Summary : Clinical Interpretation of Genomic Variants from Large Next-Generation Panel (NGS), Whole Exome Sequencing and Whole Transcriptome Sequencing
Deadline : 02 Jun 2020
Other Information
Notice Type : Tender
TOT Ref.No.: 43058410
Document Ref. No. : 75N91020Q00029
Competition : ICB
Financier : Self Financed
Purchaser Ownership : -
Tender Value : Refer Document
Purchaser's Detail
Purchaser : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Contracting Office Address : Rockville, MD 20850
Primary Point of Contact : Adam Hernandez
adam.hernandez@nih.gov
Phone Number 2402765633
USA
Email :adam.hernandez@nih.gov
Tender Details
Clinical Interpretation of Genomic Variants from Large Next-Generation Panel (NGS), Whole Exome Sequencing and Whole Transcriptome Sequencing
Active Contract Opportunity
Notice ID : 75N91020Q00029
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office : NIH National Cancer Institute
General Information
Contract Opportunity Type: Special Notice (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: May 22, 2020 02:45 pm EDT
Original Response Date: Jun 02, 2020 09:00 am EDT
Inactive Policy: 15 days after response date
Original Inactive Date: Jun 17, 2020
Initiative: None
Classification
Original Set Aside:
Product Service Code: Q301 - MEDICAL- LABORATORY TESTING
NAICS Code: 541990 - All Other Professional, Scientific, and Technical Services
Place of Performance:
Description
The U.S. Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Pathology (LP) intends to procure, on a sole source basis, services for the clinical interpretation of genomic variants from large next-generation panel (NGS), whole exome sequencing and whole transcriptome sequencing from Qiagen, LLC, 19300 Germantown Road, Germantown, MD 20874-1415, United States.
The response close date of the notice for this requirement is in accordance with FAR 5.203(b). This acquisition will be processed under FAR Part 12 Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1(b)(2); and is exempt from the requirements of FAR Part 6. The North American Industry Classification System (NAICS) code is 541990 and the business size standard is $16.5 million.
1.0 BACKGROUND
The Clinical Oncologic Molecular Pathology Sequencing Service (COMPASS) program in the Laboratory of Pathology (LP) located in the Cancer Center for Research (CCR) at the National Cancer Institute (NCI) is committed to advancing genomic research and offering genomic testing so that new treatments, therapies and therapeutics against cancer can be developed. The COMPASS program is developing large NGS panels, whole exome sequencing and whole transcriptome sequencing assays to identify genetic changes in clinical specimens from cancer patients who are being evaluated and/or treated by the intramural program of the National Cancer Institute. These genetic changes include mutations, copy number changes and gene rearrangements. Given the massive amount of genetic data generated from NGS assays and rapidly changing information on clinical trials, professional guidelines, and public databases, it is challenging for the Laboratory of Pathology to accurately surv...
Documents
Tender Notice